Transient local burning or itching has been reported with I.V. administration of Ranitidine.
The relationship of therapy with Ranitidine has been unclear in many cases. Headache, sometimes severe, seems to be related to administration of Ranitidine.
Central Nervous System: Rarely, malaise, dizziness, somnolence, insomnia and vertigo. Rare cases of reversible mental confusion, agitation, depression and hallucinations have been reported predominantly in severely ill elderly patients. Rare cases of reversible blurred vision suggestive of a change in accommodation have been reported. Rare reports of reversible involuntary motor disturbances have been received.
Cardiovascular: As with other H2-blockers, rare reports of arrhythmias such as tachycardia, bradycardia, asystole. Atrioventricular block and premature ventricular beats.
Gastrointestinal: Constipation, diarrhea, nausea, vomiting, abdominal discomfort/pain and rare reports of pancreatitis.
Musculoskeletal: Rare reports of arthralgia and myalgias.
Hematologic: Blood count changes (leukopenia, granulocytopenia and thrombocytopenia) have occurred in a few patients. These were usually reversible. Rare cases of agranulocytosis, pancytopenia, sometimes with marrow hypoplasia and aplastic anemia and exceedingly rare cases of acquired immune hemolytic anemia have been reported.
Endocrine: Controlled studies in animals and humans have shown no stimulation of any pituitary hormone by ranitidine and no antiandrogenic activity, and cimetidine induced gynecomastia and impotence in hypersecretory patients have resolved when ranitidine has been substituted. However, occasional cases of gynecomastia, impotence, and loss of libido have been reported in male patients receiving Ranitidine, but the incidence did not differ from that in the general population.
Integumentary: Rash, including rare cases of erythema multiforme, and rarely, alopecia.
Other: Rare cases of hypersensitivity reactions (e.g. bronchospasm, fever, rash, eosinophilia) anaphylaxis. Angioneurotic edema, and small increases in serum creatinine.
View ADR Reporting Link